Sermorelin Peptide: What the Research Record Shows

The short version

Sermorelin is a 29-amino-acid analog of human growth hormone-releasing hormone, and it is one of the few peptides on the research market that once carried a real FDA approval and then lost it. Two applications were approved, NDA 19-863 in December 1990 and NDA 20-443 in September 1997. Both were discontinued by the sponsor in 2008, and the FDA withdrew approval of both effective June 18, 2009.^[2] There is no current FDA-registered label for sermorelin in the United States; a search of DailyMed in August 2026 returns zero structured product labels for the ingredient.

That history is the single most important thing to understand about sermorelin, because it explains why almost everything written about the peptide today cites evidence that stopped accumulating roughly thirty years ago.

What sermorelin is

Endogenous GHRH is a 44-amino-acid hypothalamic peptide. Sermorelin is GHRH(1-29)NH2 — the first 29 residues with a C-terminal amide. In their 1999 review, Prakash and Goa describe it as the shortest synthetic peptide with full biological activity of GHRH.^[3]It acts on pituitary somatotrophs to stimulate growth hormone secretion, one step upstream of growth hormone itself, which is the mechanistic argument its advocates lean on: the pituitary’s own feedback loops stay in place.

The same 29-residue backbone underlies several later analogs. Tesamorelin is GHRH(1-44) with an N-terminal acyl group; CJC-1295 is a modified GHRH(1-29). The relationship matters when reading claims made about the whole class rather than about sermorelin specifically, a distinction worth holding onto when comparing this record with the CJC-1295 and ipamorelin evidence.

The two FDA approvals, and what each was actually for

The 2013 Federal Register determination lays out both indications precisely.^[1]

NDA 19-863 covered GEREF injection at 0.05 mg base per ampule, approved December 28, 1990, and was indicated for evaluating the ability of the somatotroph of the pituitary gland to secrete growth hormone. This was the diagnostic product, later marketed as Geref Diagnostic.

NDA 20-443 covered GEREF injection at 0.5 mg and 1.0 mg base per vial, approved September 26, 1997 under orphan designation, and was indicated for the treatment of idiopathic growth hormone deficiency in children with growth failure.

Note what is not there. Neither approval covered adults. Neither covered body composition, sleep, recovery, or aging. The only approved treatment indication in the drug’s entire regulatory history was pediatric growth failure.

EMD Serono notified FDA in July 2008 that the diagnostic ampule was being discontinued, and in December 2008 requested withdrawal of both applications. FDA later determined, in response to a 2012 citizen petition, that neither product was withdrawn from sale for reasons of safety or effectiveness. That determination is often quoted as an endorsement. It is not. It is a narrow finding that clears the path for generic applications, and FDA states plainly that it reviewed its files and the literature and found no safety or effectiveness signal behind the withdrawal. Commercial reasons are the usual explanation, and the agency does not name one.

What the pediatric growth trials found

The treatment evidence is real but small, and it consistently places sermorelin below growth hormone.

Neyzi and colleagues randomized 43 prepubertal children with GHD of hypothalamic origin to low-dose GHRH(1-29)NH2 (30 µg/kg/day in three doses, n=15), high-dose (60 µg/kg/day in three doses, n=12), or growth hormone (0.1 IU/kg/day, n=16) for six months.^[4] Height velocity was lowest in the low-dose group and comparable between the high-dose and GH groups — but height standard deviation score for bone age increased only in the GH group.

Ogilvy-Stuart and colleagues treated nine children with radiation-induced GHD using 15 µg/kg twice daily for a year.^[5] Height velocity rose from 3.3 cm/year to 6.0 cm/year (P=0.004). In the following year on growth hormone, the same children grew 7.5 cm/year.

Prakash and Goa’s review reached the summary judgment that still stands: increases in height velocity with subcutaneous sermorelin were less than those in children receiving once-daily subcutaneous somatropin, and the effect of long-term treatment on final adult height was yet to be determined.^[3] That question was never answered. The commonly reported adverse events were transient facial flushing and injection-site pain.

An intranasal formulation was tested in eight children over six months.^[7] Anti-GHRH antibodies, initially negative, turned positive in three of eight patients by six weeks, and six-month stadiometric height velocity did not increase.

The pharmacokinetic problem that ended the program

Sermorelin is cleaved by dipeptidyl peptidase IV. Bai and Chang showed the major metabolite is GRF(3-29)NH2, which is inactive^[8] — the same enzymatic vulnerability that later analogs were explicitly engineered around.

In rats, the plasma half-life of GRF(1-29)-amide after IV injection was 6.2 minutes, with about 5.1% of a subcutaneous dose reaching the circulation.^[9] Those are animal figures and should not be read as human values. Human data are thinner: Wilton and colleagues found sermorelin was rapidly eliminated after intravenous injection in 30 healthy men, though GH levels stayed elevated for about three hours, and intranasal bioavailability was only 3–5%.^[6] A precise human half-life figure appears in the original Geref labeling, which survives only as scanned pre-1996 FDA documents that are not machine-readable, so this article does not assert one. If you see a specific number quoted online without a citation, treat it as unverified. For how these figures are derived and why they matter, see the peptide half-life guide.

The industry’s own verdict is in a 2005 Serono-authored paper on a PEGylated GHRH, which opens by stating that the clinical use of growth hormone-releasing hormone is limited by its short half-life.^[10] The company was trying to replace sermorelin, not defend it.

The hole sermorelin left in endocrine diagnostics

The diagnostic use was the more durable one, and its disappearance is documented in an unusually direct way. The GHRH-plus-arginine test was a standard alternative to the insulin tolerance test for diagnosing adult GHD. When Geref Diagnostic was pulled, that test became unavailable in the United States.

The macimorelin validation study records the moment: after 43 patients with adult GHD and 10 controls had been tested, the GHRH analog Geref Diagnostic became unavailable in the United States, and the trial had to be completed with macimorelin alone.^[11] A separate review notes the unavailability of the GHRH-arginine test in the US since 2008 and the resulting shift toward glucagon stimulation testing.^[12]

The gap was eventually filled by macimorelin (Macrilen), an oral ghrelin mimetic approved December 20, 2017 under NDA 205598^[13] — nine years after the GHRH test went dark.

What the record does not contain

This is where sermorelin’s modern marketing and its evidence base diverge most sharply.

A registry check is the fastest way to see it. Searching ClinicalTrials.gov in August 2026 with term expansion disabled returns zero studies naming sermorelin. The same strict search returns 22 for tesamorelin and 2 for ipamorelin. Expanded searches surface dozens of GHRH trials, but on inspection those use tesamorelin (TH9507), generic GHRH preparations, or GHRH antagonists. Two registered trials of GHRH in the elderly exist, and both were terminated — one at 5 participants when the investigator left the institution, one at 13 when funding ended. If you want to check this yourself, the method is covered in reading ClinicalTrials.gov.

The published literature is similarly thin. Only 24 papers have sermorelin in the title or abstract in all of PubMed. The randomized trials indexed under the term cluster in 1986–2005, and none after that studied sermorelin as a therapy.

A 2020 review of growth hormone secretagogues in hypogonadal men, which covers sermorelin explicitly, concluded that current data on their clinical efficacy largely remain lacking.^[15] A 2026 review in Sports Medicine places sermorelin in the gray market of compounds where rigorous human safety data are scarce.^[16]

There is a frequently cited 2006 item titled “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?” Its PubMed record shows a two-page article with no abstract. It is a commentary, not a trial report, and it is regularly cited as though it were evidence of efficacy in adults. It is not.

Anti-doping status

GHRH and its synthetic analogs are prohibited by the World Anti-Doping Agency. A 2021 King’s College London paper developed detection methods for four GHRH analogs including sermorelin, using the metabolite sermorelin(3-29)-NH2 as a marker, and reached limits of detection generally at or below the 1 ng/mL WADA performance requirement.^[14] The same paper notes that despite admissions and intelligence indicating use, these compounds have not commonly turned up in accredited laboratory samples.